Table 1.
Summary of commonly reported AEs by intervention.
| At least 1 AE | Infections | GI | Amenorrhea | Hematological | Death | |
|---|---|---|---|---|---|---|
| and/or ovarian complications | ||||||
| MMF | ||||||
| RCTs (n = 5) | 96.2–97.3% | 12.5–68.5% | 9.1–61.4% | 0–6% | 0–21.7% | 1.9–5.0% |
| Observational (n = 5) | 42.8–66.7% | 3.85–44.4% | 4.2–38.9% | N/A | 0.5–5.6% | N/A |
| MTX | ||||||
| RCTs (n = 1) | 93.0% | 4.9% | 56.1% | N/A | 26.8% | N/A |
| Observational (n = 0) | N/A | N/A | N/A | N/A | N/A | N/A |
| AZA | ||||||
| RCTs (n = 7) | N/A | 2.4–42.4% | 3.2–21.4% | 8–36% | 6–50% | 0–25% |
| Observational (n = 3) | N/A | N/A | 1.3% | 1.4–5.6% | 16.7% | N/A |
| IVC | ||||||
| RCTs (n = 8) | 95% | 11.8–77% | 29.4–66.7% | 2.2–56.3% | 1.4–38.7% | 2.7–20% |
| Observational (n = 13) | 57.5–65% | 12.5–67.9% | 18–58.8% | 1.9–58% | 2.5–7.7% | 3.0–20% |
| Oral CYC | ||||||
| RCTs (n = 3) | N/A | 33–40% | 3.2% | 36–71% | 25.8% | 6.5–22.2% |
| Observational (n = 5) | N/A | 26–61% | 7% | 28–37% | 7% | N/A |
| CsA | ||||||
| RCTs (n = 2) | N/A | 6.4–19.4% | 17.0–30.6% | N/A | 11.1–38.3% | 4.3% |
| Observational (n = 1) | 62.5% | N/A | 3.9% | N/A | N/A | N/A |
AZA: azathioprine; CsA: cyclosporine; CYC: cyclophosphamide; IVC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; MTX: methotrexate; N/A: not available; RCT: randomized controlled trial.